Bifogade filer
Study published in European Urology Open Science confirms that Stockholm3 provides increased precision in prostate cancer diagnosis
Prenumeration
A new clinical validation study in the Värmland Region has been published in European Urology Open Science (1). The results of the study show that Stockholm3 leads to better prostate cancer diagnostics with a reduced number of examinations and lower resource consumption than current Swedish guidelines and can pave the way for future general screening of prostate cancer.
”The recently published study from Region Värmland further strengthens the clinical evidence for Stockholm3 and shows major improvements in prostate cancer diagnosis. Stockholm3 finds more aggressive tumors and enables a significant reduction in magnetic camera examinations and unnecessary biopsies. This has now been validated in clinical studies involving a total of over 75,000 men and reduces human suffering as well as costs and allocation of critical health care resources,” says David Rosén CEO at A3P Biomedical.
In brief the study shows the following results:
- Compared with current Swedish guidelines, Stockholm3 finds the same number of aggressive tumors, with a reduced number of magnetic camera examinations (-88 percent), reduced overdiagnosis (-18 percent) and fewer unnecessary biopsies (-15 percent).
- Compared with magnetic camera examinations, Stockholm3 finds more aggressive tumors (+7 percent), with a reduced number of supplementary magnetic camera examinations (-88 percent), reduced overdiagnosis (-23 percent) and fewer unnecessary biopsies (-39 percent).
Recruitment for the study was carried out in the Värmland Region between 2019 and 2020. Invitations were sent to 8,764 men, of whom 2,511 participated in the study and submitted a PSA test. Men with PSA ≥ 3 (N = 272) also performed a Stockholm3 test and magnetic camera examination. The study evaluated four different diagnostic strategies: i) National guidelines in Sweden until 2019, ii) National guidelines in Sweden from 2020, iii) Magnetic camera, and iv) Stockholm3.
The researchers behind the publication summarize the results by concluding that current guidelines have good susceptibility to aggressive prostate cancer, but with a high degree of overdiagnosis and unnecessary biopsies. Further, that Stockholm3 can significantly improve the precision of diagnostics and in the long run pave the way for general screening of prostate cancer.
To read the Region Värmland’s press release on the study, please refer to this link (in Swedish): Studie i Värmland banar väg för bättre tidig diagnostik av prostatacancer - Region Värmland (regionvarmland.se).
(1) A Head-to-head Comparison of Prostate Cancer Diagnostic Strategies Using the Stockholm3 Test, Magnetic Resonance Imaging, and Swedish National Guidelines: Results from a Prospective Population-based Screening Study; Walden et al, European Urology Open Science 2022